ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted 510(k) clearance for the iStent infinite trabecular micro-bypass system to reduce IOP as a stand ...
Please provide your email address to receive an email when new articles are posted on . According to Singh, the iStent infinite allows surgeons to inject up to three stents around Schlemm’s canal in a ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...
Novel Three-Stent Injectable System Designed to Provide Foundational, 24/7 IOP Control ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Glaukos’ GKOS iStent infinite Trabecular Micro-Bypass System indicated for use in a standalone procedure to reduce elevated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback